Repeal of Regulation (EC) No 726/2004 on granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Comirnaty - tozinameran, COVID-19 mRNA vaccine (nucleoside-modified)", a medicinal product for human use

This procedure involves a formal objection to a European Commission decision regarding the marketing authorisation of the Comirnaty mRNA vaccine. It focuses on the legal and regulatory process used to approve the vaccine for use across the European Union under existing pharmaceutical legislation.

This affects the European Commission and regulatory bodies. It examines the validity of the vaccine's authorization and the repeal of previous decisions concerning its market entry.